<PAGE>
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
-------------------------
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
-------------------------
DATE OF REPORT: February 7, 2000
(Date of earliest event reported)
PHOTOGEN TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)
NEVADA 0-23553 36-4010347
(State or other jurisdiction (Commission File Number) (I.R.S. Employer
of incorporation or Identification No.)
organization)
7327 OAK RIDGE HIGHWAY, SUITE B
KNOXVILLE, TENNESSEE 37931
(Address of principal executive offices) (Zip Code)
(423) 769-4011
(Registrant's telephone number including area code)
<PAGE>
ITEM 5.OTHER EVENTS.
Photogen Technologies, Inc. (the "Company") issued a press release
announcing that it has initiated a formal search for a new Chief Executive
Officer. The Press Release, dated February 7, 2000, is attached as Exhibit
99 hereto.
ITEM 7. FINANCIAL STATEMENTS AND EXHIBITS.
(c) The following exhibit is filed with this report:
99 Press release of the Company, dated February 7, 2000, announcing
that it has initiated a formal search for a new Chief Executive
Officer
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Photogen Technologies, Inc.
By: /s/ Tim Scott
--------------------------
Tim Scott, Vice President
Date: February 8, 2000
<PAGE>
EXHIBIT INDEX
Exhibit Description
No.
99 Press release of the Company, dated February 7, 2000, announcing
that it has initiated a formal search for a new Chief Executive
Officer
<PAGE>
Exhibit 99
PHOTOGEN TECHNOLOGIES ANNOUNCES EXECUTIVE SEARCH
Company Expansion Triggers Management Restructure
KNOXVILLE, TENN., Feb. 7, 2000 -- The Board of Directors of Photogen
Technologies, Inc. (NASDAQ: PHGN) today announced that it has initiated a
formal search for a new Chief Executive Officer for the Company along with a
management restructuring effective immediately.
"Photogen Technologies has developed rapidly since its inception in 1997. It
is time for the founders to turn over management to a seasoned professional
who will lead the company through clinical trials, regulatory approvals and
product development," said John Smolik.
As part of the restructuring, Smolik steps down from the positions of
Chairman, CEO and President of Photogen Technologies. Those positions will be
filled on an interim basis by Timothy Scott, Ph.D., who previously held the
positions of Vice President and Chief Operating Officer.
Smolik will continue as a Director with the Company and retain the positions
of Chairman and President of Photogen, Inc., the principal operating
subsidiary of Photogen Technologies. Smolik also remains a director of
Sentigen Ltd., Photogen's 80 percent joint venture subsidiary with Elan
Corporation. Smolik will hold these positions until the new CEO is on board.
ABOUT PHOTOGEN
Photogen Technologies, Inc. is a development-stage company focused on
creating therapeutic and diagnostic products based on its proprietary
multi-photon excitation and other related technologies. The company has
discovered new methods for using energy from lasers, X-rays or other sources
to activate photoactive agents within tissue sufficient to produce a range of
beneficial therapeutic and diagnostic outcomes. These technologies involve
methods, materials and devices that may be used to produce light or other
energy and photoactive agents and to destroy diseased cells, remove tissue or
identify and diagnose disease. Photogen has U.S. patents and additional
pending applications in the U.S. and elsewhere for certain of its proprietary
technology. The company has no diagnostic or therapeutic products at this
time.
Statements in this release that are not strictly historical are
"forward-looking" statements that are made pursuant to the safe harbor
provision of the Private Securities Litigation Reform Act of 1995.
<PAGE>
Forward-looking statements involve known and unknown risks, which may cause
the company's actual results in the future to differ materially from expected
results. These risks are qualified in their entirety by cautionary language
and risk factors set forth in the company's filings with the Securities and
Exchange Commission.
Media Contacts: Hilary Kaye or Joan Murray at Hilary Kaye Associates (714)
426-0444 (PST) or [email protected].
Investor Relations Contact: Jonathan Fassberg at The Trout Group (212)
477-9007 (EST) or [email protected].
###
